Siemens Healthineers Wins FDA Nod for AI Imaging Suite as Diagnostics Crisis and Spin-Off Plan Dominate Investor Attention

Imaging portfolio clears US regulatory hurdles, but diagnostics revenue slides 6.5% and stock nears 52-week low as Siemens plans diagnostics carve-out.

Siemens Healthineers has secured six US regulatory approvals for its Artis interventional imaging portfolio, a rare bright spot in a quarter that otherwise laid bare the deepening problems in its diagnostics division. The clearance clears the way for broader hospital adoption of the company’s Optiq AI imaging chain, which uses deep-learning noise reduction to optimise image data in real time. But the news, alongside a planned change at the technology helm, has done little to lift a stock trading barely a euro above its 52-week low.

The diagnostics unit, which has become the group’s most persistent headache, saw revenues shrink 6.5% in the latest quarter while its adjusted operating margin collapsed to just 0.9%. By contrast, the imaging segment grew 6.1% and the cancer therapy arm Varian added 7.5% — highlighting the starkly divided nature of the business. Management responded by trimming its full-year 2026 outlook, now targeting revenue growth of 4.5% to 5.0% and adjusted earnings per share of €2.20 to €2.30, down from the previous upper end of €2.30.

Investors have already voted with their feet. The shares closed Friday at €34.51, a slight 0.52% decline on the day but up 3.51% over the week — a pattern that sums up the tentative recovery narrative. Year to date, the stock has lost 22.34%, and over 12 months the decline stands at 28.49%, leaving it 30.79% below its 52-week high. The 200-day moving average, a widely watched long-term indicator, sits at roughly €43, underscoring how far the shares have fallen from grace.

Market observers remain sharply divided on the outlook. Deutsche Bank cut its price target to €38 while keeping a “Hold” rating, arguing that a rapid margin recovery is essential. Jefferies slashed its target more aggressively, from €60 to €50, but maintained its buy recommendation. At the other end of the spectrum, JPMorgan sits at almost €56, and the consensus analyst target hovers around €49. The wide dispersion reflects the uncertainty around both the diagnostics turnaround and the group’s wider strategic overhaul.

That overhaul took a further step forward with the launch of a formal process to carve out the diagnostics unit. Siemens, which currently owns just over 67% of Healthineers, plans to transfer roughly 30% of the subsidiary’s shares directly to its own shareholders, with a longer-term goal of cutting its holding to below one-fifth. A potential spinoff would also remove a significant financial support: Siemens currently guarantees up to €13.9 billion in loans, a backstop that would disappear after separation, though a banking syndicate is already lined up for refinancing.

The company is simultaneously refreshing its technology leadership. Martin Stumpe, a former Google Brain developer, will take over as chief technology officer in June 2026, replacing Peter Schardt in a move that signals an accelerated push into AI-driven healthcare. Stumpe’s appointment follows the departure of Schardt and three other executives, part of a broader leadership shakeup aimed at sharpening the group’s digital strategy.

In the near term, all eyes are on the investor roadshows that kicked off this week, including appearances at the dbAccess conference in Frankfurt and meetings in Scandinavia. The management team must convince sceptics it has a credible plan for fixing the China headwinds — sinking reimbursement rates have been a major drag on diagnostics — and for restoring margins without sacrificing growth. A key external data point arrives later in the week with the US PCE price index, which will influence financing costs for capital-intensive medical equipment.

Until more concrete orders materialise from the FDA clearances or the diagnostics carve-out gains sharper definition, the stock is likely to remain range-bound near its 52-week trough of €33.34. The recent bounce from that level offers some technical hope, but without a clear path to profitability in the struggling division, Siemens Healthineers remains a turnaround story with an excellent core business and one very weak link.